新光药业(300519) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥92,296,717.31, a decrease of 9.42% compared to ¥101,895,419.99 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥30,445,257.47, down 28.90% from ¥42,819,141.85 year-on-year[4] - The net profit for the reporting period decreased by 28.90% to ¥30,445,257.47 compared to ¥42,819,141.85 in the previous period, primarily due to a decline in operating income, rising raw material prices, and reduced bank interest income[3] - Earnings per share (EPS) for Q1 2023 was CNY 0.19, compared to CNY 0.27 in the previous year[22] Cash Flow - The net cash flow from operating activities decreased by 52.79% to ¥28,027,614.00 from ¥59,363,672.75 in the previous year[4] - The net cash increase from operating activities for Q1 2023 was CNY 1,901,807.18, compared to CNY 15,437,078.93 in Q1 2022, indicating a decrease of approximately 87.7%[24] - Cash flow from operating activities generated a net amount of CNY 28,027,614.00, significantly lower than CNY 59,363,672.75 in Q1 2022[23] - The company's cash and cash equivalents increased slightly to ¥623,931,587.44 from ¥622,029,780.26 at the beginning of the year[17] Assets and Liabilities - The company's total assets at the end of Q1 2023 were ¥962,178,694.98, a decline of 1.73% from ¥979,092,999.45 at the end of the previous year[4] - Total liabilities decreased to CNY 72,704,969.26 from CNY 98,864,640.43 year-on-year[21] - The total cash and cash equivalents at the end of Q1 2023 amounted to CNY 623,931,587.44, up from CNY 609,104,874.84 at the end of Q1 2022, reflecting an increase of about 2.7%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period was 17,562, with the top 10 shareholders holding a combined 59.75% of shares[1] - Wang Yuejun is the largest shareholder, holding 61,200,000 shares, representing 38.25% of total shares[1] Investment and Expenses - The company reported a significant reduction in accounts receivable, down 65.05% to ¥8,319,064.64 from ¥23,805,357.02[8] - Total operating costs increased to CNY 57,913,730.09, up 9.5% from CNY 52,906,632.17 year-on-year[20] - Research and development expenses for Q1 2023 were CNY 3,581,334.49, a decrease from CNY 3,966,483.95 in the same period last year[21] Other Financial Metrics - The weighted average return on equity decreased to 3.48% from 4.93% year-on-year[4] - Other comprehensive income after tax decreased by 35.17% to ¥133,917.02 from ¥206,552.12, mainly due to changes in the fair value of other equity instrument investments[3] - The net cash outflow from investment activities for Q1 2023 was CNY 26,125,806.82, an improvement compared to a net outflow of CNY 43,926,593.82 in Q1 2022, representing a reduction of approximately 40.5%[24] Audit and Reporting - The report for Q1 2023 was not audited, which may affect the reliability of the financial data presented[25]